Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Endocannabinoids in arthritis: current views and perspective

Endocannabinoids in arthritis: current views and perspective Preclinical and clinical studies using cannabis‐based therapy have been shown to provide both analgesia and anti‐inflammatory effects, with an overall alleviation of clinical symptoms in animal models of arthritis, highlighting its promising therapeutic application for humans. Despite this, the development of cannabis‐based therapeutics remains in its infancy, with further investigation into its efficacy and safety profile in patients still required. This synopsis reviews the various components of the endocannabinoid system in health and disease and their potential as therapeutic targets. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Rheumatic Diseases Wiley

Endocannabinoids in arthritis: current views and perspective

Download PDF
9 pages

Loading next page...
 
/lp/wiley/endocannabinoids-in-arthritis-current-views-and-perspective-EcRk5TT8Hy
Publisher
Wiley
Copyright
International Journal of Rheumatic Diseases © 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd
ISSN
1756-1841
eISSN
1756-185X
DOI
10.1111/1756-185X.13146
pmid
28736968
Publisher site
See Article on Publisher Site

Abstract

Preclinical and clinical studies using cannabis‐based therapy have been shown to provide both analgesia and anti‐inflammatory effects, with an overall alleviation of clinical symptoms in animal models of arthritis, highlighting its promising therapeutic application for humans. Despite this, the development of cannabis‐based therapeutics remains in its infancy, with further investigation into its efficacy and safety profile in patients still required. This synopsis reviews the various components of the endocannabinoid system in health and disease and their potential as therapeutic targets.

Journal

International Journal of Rheumatic Diseases – Wiley

Published: Jul 1, 2017

Keywords: ; ; ; ;

References

  • Human studies of cannabinoids and medicinal cannabis
    Robson, P
  • The role of endocannabinoids in pain modulation
    Zogopoulos, P; Vasileiou, I; Patsouris, E; Theocharis, SE
  • Cannabinoid‐based drugs as anti‐inflammatory therapeutics
    Klein, TW
  • Medicinal use of cannabis: history and current status
    Kalant, H
  • Modulating the endocannabinoid system in human health and disease–successes and failures
    Pacher, P; Kunos, G
  • Therapeutic potential of cannabis‐related drugs
    Alexander, SPH
  • Structure of a cannabinoid receptor and functional expression of the cloned cDNA
    Matsuda, LA; Lolait, SJ; Brownstein, MJ; Young, AC; Bonner, TI
  • The endocannabinoid system as a target for the treatment of neurodegenerative disease
    Scotter, EL; Abood, ME; Glass, M
  • Biochemistry, pharmacology and physiology of 2‐arachidonoylglycerol, an endogenous cannabinoid receptor ligand
    Sugiura, T; Kishimoto, S; Oka, S; Gokoh, M
  • Dynamic changes to the endocannabinoid system in models of chronic pain
    Sagar, DR; Burston, JJ; Woodhams, SG; Chapman, V
  • Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis
    Richardson, D; Pearson, RG; Kurian, N
  • Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials
    Fitzcharles, MA; Baerwald, C; Ablin, J; Hauser, W
  • Biosynthesis and degradation of the endocannabinoid 2‐arachidonoylglycerol
    Ueda, N; Tsuboi, K; Uyama, T; Ohnishi, T
  • The pharmacology of cannabinoid receptors and their ligands: an overview
    Pertwee, RG
  • Cannabinoid receptors as therapeutic targets
    Mackie, K
  • Isolation and structure of a brain constituent that binds to the cannabinoid receptor
    Devane, WA; Hanus, L; Breuer, A
  • Cannabinoid receptors and immunity
    Klein, TW; Newton, C; Friedman, H
  • Anandamide and vanilloid TRPV1 receptors
    Ross, RA
  • Identification of an endogenous 2‐monoglyceride, present in canine gut, that binds to cannabinoid receptors
    Mechoulam, R; Ben‐Shabat, S; Hanus, L
  • 2‐Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
    Hanus, L; Abu‐Lafi, S; Fride, E
  • N‐acyl‐dopamines: novel synthetic CB(1) cannabinoid‐receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo
    Bisogno, T; Melck, D; Bobrov, MY
  • An endogenous capsaicin‐like substance with high potency at recombinant and native vanilloid VR1 receptors
    Huang, SM; Bisogno, T; Trevisani, M
  • Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?
    Fitzcharles, MA; McDougall, J; Ste‐Marie, PA; Padjen, I
  • Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor
    Porter, AC; Sauer, JM; Knierman, MD
  • The endocannabinoid signalling system: biochemical aspects
    Bisogno, T; Ligresti, A; Di Marzo, V
  • Endocannabinoid signaling and synaptic function
    Castillo, PE; Younts, TJ; Chávez, AE; Hashimotodani, Y
  • Multiple pathways involved in the biosynthesis of anandamide
    Liu, J; Wang, L; Harvey‐White, J; Huang, BX
  • Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system
    Cravatt, BF; Lichtman, AH
  • Molecular characterization of a peripheral receptor for cannabinoids
    Munro, S; Thomas, KL; Abu‐Shaar, M
  • International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
    Howlett, A; Barth, F; Bonne, T
  • The orphan receptor GPR55 is a novel cannabinoid receptor
    Ryberg, E; Larsson, N; Sjögren, S
  • Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities
    Pertwee, RG
  • The neuronal background K2P channels: focus on TREK1
    Honoré, E
  • HU‐308: a specific agonist for CB2, a peripheral cannabinoid receptor
    Hanus, L; Breuer, A; Tchilibon, S
  • Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models
    Zhang, J; Hoffert, C; Vu, HK; Groblewski, T; Ahmad, S; O'Donnell, D
  • Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS
    Ibrahim, MM; Deng, H; Zvonok, A
  • Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy
    Valenzano, KJ; Tafesse, L; Lee, G
  • Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
    Anand, P; Whiteside, G; Fowler, CJ; Hohmann, AG
  • The role of proinflammatory cytokines in the generation and maintenance of joint pain
    Schaible, HG; Von Banchet, GS; Boettger, MK
  • Why do cannabinoid receptors have more than one endogenous ligand?
    Di Marzo, V; De Petrocellis, L
  • A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols* (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis
    Novotna, A; Mares, J; Ratcliffe, S
  • Long‐term efficacy and safety of dronabinol for acquired immunodeficiency syndrome‐associated anorexia
    Beal, JE; Olson, R; Lefkowitz, L
  • The endocannabinoid system in ageing: a new target for drug development
    Paradisi, A; Oddi, S; Maccarrone, M
  • The medicinal use of cannabis in the UK: results of a nationwide survey
    Ware, MA; Adams, H; Guy, GW
  • Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
    Di Marzo, V; Melck, D; Bisogno, T; De Petrocellis, L
  • Inflammation in osteoarthritis
    Goldring, MB; Otero, M
  • The nonpsychoactive cannabis constituent cannabidiol is an oral anti‐arthritic therapeutic in murine collagen‐induced arthritis
    Malfait, A; Gallily, Sumariwalla P; Malik, A; Andreakos, E; Mechoulam, R; Feldmann, M
  • Prospects for cannabinoids as anti‐inflammatory agents
    Zurier, RB
  • A novel synthetic, nonpsychoactive cannabinoid acid (HU‐320) with anti‐inflammatory properties in murine collagen‐induced arthritis
    Sumariwalla, PF; Gallily, R; Tchilibon, S; Fride, E; Mechoulam, R; Feldmann, M
  • Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast‐like synoviocytes
    Selvi, E; Lorenzini, S; Garcia‐Gonzalez, E
  • Cortisol‐mediated adhesion of synovial fibroblasts is dependent on the degradation of anandamide and activation of the endocannabinoid system
    Lowin, T; Zhu, W; Dettmer‐Wilde, K; Straub, RH
  • Dimethylheptyl‐THC‐11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure
    Zurier, RB; Rossetti, RG; Lane, JH; Goldberg, JM; Hunter, SA; Burstein, SH
  • Suppression of human monocyte interleukin‐1beta production by ajulemic acid, a nonpsychoactive cannabinoid
    Zurier, RB; Rossetti, RG; Burstein, SH; Bidinger, B
  • Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast‐like cells
    George, KL; Saltman, Stein GS; Lian, JB; Zurier, RB
  • The molecular basis of pain and its clinical implications in rheumatology
    Bingham, B; Ajit, SK; Blake, DR; Samad, TA
  • Cannabinoids in the management of difficult to treat pain
    Russo, EB
  • Endocannabinoids in pain modulation
    Walker, J; Huang, S
  • Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints
    Krustev, E; Reid, A; McDougall, JJ
  • Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
    Jayamanne, A; Greenwood, R; Mitchell, VA; Aslan, S; Piomelli, D; Vaughan, CW
  • Cannabinoid‐mediated antinociception is enhanced in rat osteoarthritic knees
    Schuelert, N; McDougall, JJ
  • In vitro and in vivo characterization of A‐796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models
    Yao, BB; Hsieh, GC; Frost, JM; Fan, Y
  • The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors
    Dani, M; Guindon, J; Lambert, C; Beaulieu, P
  • The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors
    Ottani, A; Leone, S; Sandrini, M; Ferrari, A; Bertolini, A
  • The general anesthetic propofol increases brain N‐arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase
    Patel, S; Wohlfeil, ER; Rademacher, DJ
  • Cannabinoids in the management of musculoskeletal or rheumatic diseases
    Fitzcharles, MA; Hauser, W
  • Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials
    Fitzcharles, MA; Ste‐Marie, PA; Hauser, W
  • Cannabinoids for fibromyalgia
    Wallit, B; Klose, P; Fitzcharles, MA; Phillips, T; Hauser, W
  • Preliminary assessment of the efficacy, tolerability and safety of a cannabis‐based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
    Blake, DR; Robson, P; Ho, M; Jubb, RW; McCabe, CS
  • The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial
    Ware, MA; Fitzcharles, MA; Joseph, L; Shir, Y
  • An efficient randomised, placebo‐controlled clinical trial with the irreversible fatty acid amide hydrolase‐1 inhibitor PF‐04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee
    Huggins, JP; Smart, TS; Langman, S; Taylor, L; Young, T